Top Tweets for #EGFRMutant
The phase II #NeoLazer trial evaluates neoadjuvant lazertinib with or without chemotherapy, followed by surgery and adjuvant lazertinib, in patients with resectable #EGFRmutant #NSCLC @JCOOA_ASCO
An important step toward optimizing perioperative targeted therapy
https://t.co/yHcE5MNhl9

#ESMO26: In phase III trials, izalontamab brengitecan (#BispecificADC targeting EGFR and #HER3) and ruzaltatug rezetecan (#ADC targeting HER3) showed significant efficacy in patients with locally advanced or #metastatic #EGFRmutant #NSCLC
๐ https://t.co/H9TBIyCVWs
#InsightsbyESMO

๐จ Ep. 3 OUT NOW! Time Toxicity, CNS Risk & Sequencing Strategy in #EGFRMutant #NSCLC ๐ง ๐ซ
๐ MARIPOSA CNS data
๐SubQ amivantamab
โฐTime Toxicity
#lcsm #OncTwitter #Oncology #FOAMed @lungoncdoc @FawziAbuRous @JuliaRotow @SusanScottMD
๐๏ธWatch full ๐ฃ๏ธ๐
https://t.co/dohUMYrB7N
Updated review on approaching acquired resistance in EGFR mutant NSCLC @ESMO_Open from Dr. @LeXiuning et al. Important to uncover mechanisms of resistance whenever possible - on target, off target, bypass. Rapidly evolving space.
https://t.co/vbg5mPOEY3
PALOMA-3 trial: Significant reduction in IRRs with SC vs. IV in EFGR + NSCLC - @chulkimMD
@ASCO
#Cancer #EGFRMutant #NSCLC #OncoDaily #Oncology #ClinicalTrial
https://t.co/41KbnFf6lb
Osimertinib (Tagrisso) has revolutionized tx of #EGFRmutant #NSCLC, improving overall survival in both resectable + metastatic disease. But we still do not know how best to use it in unresectable stage III disease, where concurrent chemoradiation (cCRT) is the local tx of choice.

Fantastic discussion of amazing plenary data @asco23 by fabulous @bensolomon1 #egfrmutant #NSCLC @PeterMacCC @PeterMacRes

Congrats @bensolomon1 for the great discussion of the unprecedented OS data of ADAURA. Important to guarantee access to medication for our patients around the world and TESTING! Great slide by @jillfeldman4 on toxicity considerations. #ASCO23 @EGFRResisters @asco @isliquidbiopsy

#ASCO23 @ASCO
Day 1 #LCSM
#EGFRMutant #NSCLC
๐CSS at 1p CDT S406
โจProgress over 2O y
โจ Neoadjuvant Osi
โจ Again Study (TKI+/-Chemo)
โจ MET IHC in 2nd Line EGFR+
@salmanpunekar @MNagasaka Drs. Sarah Goldberg, Pasi Janne
@EGFRResisters @jillfeldman4
@OncoAlert
Indeed, an area of unmet needs and much needed trials.
CNS mets/CNS progression on 1st line Osimertinib in patients with #EGFRMutant #NSCLC
Thx for sharing @VivekSubbiah
#AACR21
๐จโญ๏ธCNS mets & CNS progression on 1st line osimertinib is an unmet need. Looking forward to trials targeting this area @AACR #AACR21 @OncoAlert @StephenVLiu @n8pennell

We also report frequent complex intragenic rearrangements in #EGFRmutant lung tumors which associated with SCLC/SCC histologic transformation.
#NSCLC: the benefit of the #antiPD1(L1) appears to be less efficacious in pre-treated #EGFRmutant. Current state by #RossSoo et al @OncologyAdvance https://t.co/X308RBPsi1

Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users

Elon Musk 
@elonmusk
240.4M followers

Barack Obama 
@barackobama
118.7M followers

Cristiano Ronaldo 
@cristiano
114.4M followers

Donald J. Trump 
@realdonaldtrump
111.8M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
91.7M followers

KATY PERRY 
@katyperry
90M followers

Taylor Swift 
@taylorswift13
83.9M followers

Lady Gaga 
@ladygaga
75.4M followers

Virat Kohli 
@imvkohli
73.3M followers

Kim Kardashian 
@kimkardashian
70.8M followers

YouTube 
@youtube
68.7M followers

Neymar Jr 
@neymarjr
66.3M followers

Bill Gates 
@billgates
65.2M followers

Selena Gomez 
@selenagomez
63M followers

The Ellen Show
@theellenshow
62.1M followers

CNN 
@cnn
61.7M followers

X 
@x
60.6M followers















